- NCIt
- C3693
Loading cancer entity…
Loading cancer entity…
Clinical trials
221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05371223 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases(Nab-PIPAC) | unknown | Phase 2 | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05541146 | Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER |
| 1 |
| Mar 23, 2023 |
| clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT04797923 | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination | unknown | Phase 2 | 43 | Gangnam Severance HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04734691 | Second Line Oxaliplatin Based Chemotherapy Alone Versus Oxaliplatin Based PIPAC and Chemotherapy in Colorectal Peritoneal Carcinomatosis : A Phase II Randomize Mutli-centric Study(OPAC) | unknown | Phase 2 | 50 | Sleiman Marwan-JulienOTHER | 0 | Feb 2, 2021 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03699332 | Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin(MMIPC) | unknown | Phase 1 / Phase 2 | 29 | Radboud University Medical CenterOTHER | 1 | Sep 13, 2019 | clinicaltrials |
| NCT01818713 | Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases | unknown | Phase 2 | 6 | The Netherlands Cancer InstituteOTHER | 1 | Oct 29, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 26, 2024source: clinicaltrials